All In Biotech

Drug Trial Radar · NCT01557998

Testing and Linkage to Care for Injecting Drug Users in Kenya

Testing and Linkage to Care for IDUs in Kenya (TLC-IDU Kenya); HCV Among PWIDs in Kenya: A Supplement to the TLC-IDU Study

Last checked: Nov 19, 2026Latest source record: Oct 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 9,449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,449

Actual

Start

May 2012

Primary completion

Apr 30, 2016

Study completion Apr 30, 2018

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NYU Langone Health; Kenya National AIDS & STI Control Programme; National Institute on Drug Abuse (NIDA)
First posted
Mar 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Testing and Linkage to Care for Injecting Drug Users in Kenya: Interventions for people who inject drugs (PWID) in sub-Saharan African have been almost entirely absent, despite the fact that in countries like Kenya they contribute a growing proportion of incident HIV infections. This study will leverage a historic decision in Kenya to launch needle exchange program (NSP) and related services for this most-at-risk population (MARP). The investigators will use this NSP/MARP platform to seek out PWID, deliver rapid HIV testing, point of care CD4 count and link to ART using peer case managers, and evaluate community viral load impact using a stepped wedge cluster-randomized design. Lessons learned will have important applicability throughout sub-Saharan African. HCV Among PWID in Kenya: A Supplement to the TLC-IDU study: The prevalence of HCV in Kenya, where an increasing number of people who inject drugs (PWID) live and are becoming HIV- as well as HCV-infected, has not been defined. We will establish HCV prevalence among PWID in Nairobi, Western, and Coastal region by adding HCV rapid and confirmatory tests in our parent PWID study (TLC-IDU Kenya); deliver appropriate counseling and treatment options to those eligible; collect HCV treatment adherence data; and disseminate study findings. These data will provide novel and relevant information about HCV and HIV co-infection in Kenya among PWID that will be immediately applicable in terms of public health impact to national and regional HCV testing, counseling, and clinical management policy.

Conditions

  • HIV Infection
  • HCV Coinfection

Interventions

  • POC CD4 and Peer Case ManagementBehavioral

    HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.

  • HCV+PWIDDrug

    Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.

  • Control - No interventionBehavioral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Linkage to care and time to ARTTime frame: Data collection done in 5 waves separated by 6 months
  2. Community viral load before and after the TLC-IDU initiationTime frame: Data collection done in 5 waves separated by 6 months
  3. Retention in CareTime frame: Data collection done in 5 waves separated by 6 months
  4. HCV prevalence determinationTime frame: Data collection done in wave 6 - 6-month-period
  5. HCV testing and counseling feasibility and acceptability measuresTime frame: Done in wave 6 - 6-month-period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National AIDS/STD Control Programme (NASCOP)

    Nairobi, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.